Doctors often rely on biomarkers – objective, easily measured biological features that indicate underlying pathology— to support accurate diagnosis and treatment efforts. Blood pressure, for example, is a widely-used biomarker for cardiovascular disease. Today, no comparable measures exist for FTD. The Association for Frontotemporal Degeneration (AFTD) aims to address these challenges with the award of $2 million to fund cutting-edge research into the discovery of FTD biomarkers.
After reviewing proposals from leading researchers worldwide, an expert panel has selected five researchers for multi-year FTD Biomarker awards. Recently released on PRNewswire, the full press release can be seen here.
AFTD is excited to share that The Lauder Foundation and the Samuel I. Newhouse Foundation have each committed $5 million to create The Treat FTD Fund, which will accelerate clinical trials for FTD over the next decade. The fund, a joint program of AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF), has the potential to advance treatments for other neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s. Read the press release, and see coverage of the announcement in USA Today, Alzheimer’s News Today, NJ.Com, The Chronicle of Philanthropy, and Practical Neurology.
On May 10th, AFTD announced they would hold their 2016 education conference in Minneapolis, MN, at the DoubleTree by Hilton Hotel Minneapolis-Park Place, on Friday, May 13. It will run from 9:30 a.m. to 5:30 p.m., followed by a dinner reception. Each year, AFTD hosts this important conference so that people impacted by FTD can meet in person and share resources and information. Hundreds of FTD experts, researchers, medical professionals, caregivers and persons diagnosed gather to make this annual event one of crucial importance for all impacted by FTD. The full press release can be seen here.
On Thursday, October 1, before a hopeful crowd of more than 200 at One World Trade Center in New York City, the Samuel I. Newhouse Foundation, Inc. announced a $5.75 million gift to The Association for Frontotemporal Degeneration for a multi-year FTD Biomarkers Initiative. Read the full press release here.
On October 1, AFTD, with President of Advance Publications, Inc. Donald Newhouse, convened supporters and community members to host an inaugural event at One World Trade Center. Together, we gathered to kick off U.S. participation in the first ever World FTD Awareness Week, observed from October 4th through October 11th, 2015. The full press release can be viewed here.